Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody.

Smith, Franz O; Goff, Stephanie L; Klapper, Jacob A; Levy, Catherine; Allen, Tamika; Mavroukakis, Sharon A; Rosenberg, Steven A

Smith, Franz O; Goff, Stephanie L; Klapper, Jacob A; Levy, Catherine; Allen, Tamika; Mavroukakis, Sharon A; Rosenberg, Steven A.

J Immunother ; 30(1): 130, 2007 Jan.

Article in En | MEDLINE | ID: mdl-17198092

Subject(s)

Antibodies, Monoclonal/adverse effects; Interleukin-2/adverse effects; Intestinal Perforation/chemically induced; Antibodies, Monoclonal/therapeutic use; Carcinoma, Renal Cell/therapy; Humans; Interleukin-2/administration & dosage; Interleukin-2/immunology; Ipilimumab; Kidney Neoplasms/therapy; Melanoma/therapy

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Interleukin-2 / Intestinal Perforation / Antibodies, Monoclonal Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Immunother Journal subject: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Year: 2007 Type: Article

Fulltext

XML

PubMed Links

Search on Google